Kidney cancer in 2016: The evolution of anti-angiogenic therapy for kidney cancer. Review uri icon

Overview

abstract

  • Tyrosine kinase inhibitors that target pro-angiogenic pathways improve progression-free and overall survival in patients with metastatic kidney cancer and were thus tested in the adjuvant setting in studies published this past year. 2016 also saw the emergence of new inhibitors of pro-angiogenic pathways that might represent the next step in kidney cancer therapy.

publication date

  • January 19, 2017

Research

keywords

  • Angiogenesis Inhibitors
  • Carcinoma, Renal Cell
  • Kidney Neoplasms

Identity

PubMed Central ID

  • PMC5573185

Scopus Document Identifier

  • 85010066657

Digital Object Identifier (DOI)

  • 10.1038/nrneph.2016.194

PubMed ID

  • 28100904

Additional Document Info

volume

  • 13

issue

  • 2